Nestle will pay US$2 billion to buy the remaining stake in Aimmune Therapeutics Inc, gaining full ownership of the first US-approved peanut allergy treatment.
WATCH MORE:
SUBSCRIBE:
LIKE:
Nestle will pay US$2 billion to buy the remaining stake in Aimmune Therapeutics Inc, gaining full ownership of the first US-approved peanut allergy treatment.
WATCH MORE:
SUBSCRIBE:
LIKE:
